Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders
NCT00001238
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
We will investigate the clinical manifestations and molecular genetic defects of heritable urologic malignant disorders. Families with urologic malignancy with known or suspected genetic basis will be enrolled. Affected individuals or individuals suspected of having a germline urologic malignant disorder will undergo periodic clinical assessment and genetic analyses for the purpose of: 1) definition and characterization of phenotype, 2) determination of the natural history of the disorder, and 3) genotype/phenotype correlation.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Kidney Cancer
- Urologic Malignant Disorders
- Renal Cell Carcinoma
- Familial Renal Cancer (FRC)
- Clear Cell Renal Cancer
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 2 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Cancer Institute (NCI)
- Last updated on ClinicalTrials.gov
- August 24, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Maryland · 1
- National Institutes of Health Clinical Center · Bethesda, MD
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.